Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by oral route for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with an unmet medical need, announces today that its management team will present the Company’s financial results for the first half of 2022 on Thursday, September 22 2022, during a webcast presentation.
Inventiva’s first-half 2022 financial results will be released on Wednesday September 21, 2022 at 4:00 p.m. (New York), 10:00 p.m. (Paris).
A conference call, followed by a question and answer session, moderated by Frédéric Cren, Chairman and CEO and co-founder of Inventiva, Pierre Broqua, Scientific Director and co-founder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will be held in English on Thursday, September 22, 2022 at 8:00 a.m. (New York), 2:00 p.m. (Paris).